Litcius/Paper detail

Blockage of MLKL prevents myelin damage in experimental diabetic neuropathy

Jia Guo, Zehui Guo, Yan‐Ju Huang, Suchen Ma, Bo Yan, Chenjie Pan, Zhaodi Jiang, Fengchao Wang, Zhiyuan Zhang, Yuwei Da, Xiaodong Wang, Zhengxin Ying

2022Proceedings of the National Academy of Sciences18 citationsDOIOpen Access PDF

Abstract

SignificanceDiabetic neuropathy is a commonly occurring complication of diabetes that affects hundreds of millions of patients worldwide. Patients suffering from diabetic neuropathy experience abnormal sensations and have damage in their peripheral nerve axons as well as myelin, a tightly packed Schwann cell sheath that wraps around axons to provide insulation and increases electrical conductivity along the nerve fibers. The molecular events underlying myelin damage in diabetic neuropathy are largely unknown, and there is no efficacious treatment for the disease. The current study, using a diabetic mouse model and human patient nerve samples, uncovered a molecular mechanism underlying myelin sheath damage in diabetic neuropathy and provides a potential treatment strategy for the disease.

Topics & Concepts

MyelinDiabetic neuropathyDiabetes mellitusPeripheral neuropathyMedicineSchwann cellComplicationDiseaseMyelin sheathNeurosciencePathologyInternal medicineEndocrinologyBiologyCentral nervous systemPain Mechanisms and TreatmentsBotulinum Toxin and Related Neurological DisordersNerve injury and regeneration
Blockage of MLKL prevents myelin damage in experimental diabetic neuropathy | Litcius